Led by Founder and CEO Doug Ethell, Leucadia Therapeutics has looked at Alzheimer’s disease with new eyes. We have assembled an amazing team of dedicated professionals who are focused on CURING Alzheimer’s disease.
This mission-oriented team discovered a major trigger for Alzheimer’s disease pathology and has developed a patented strategy to correct that condition.
Leucadia Therapeutics has begun a 2,000 person clinical study called, Project Cribrose. Project Cribrose participants will sit for a 20 second CT scan and undergo a battery of cognitive tests developed by Leucadia Therapeutics. The study will produce data for deep learning analysis of behavioral and morphological changes that may provide reliable biomarkers for pending Alzheimer’s disease. Project Cribrose is a collaboration with Neurosurgeons at Arrowhead Regional Medical Center. The study design has been reviewed and approved by Arrowhead Regional Medical Center’s Institutional review board (ARMC IRB #19-11).